T

he Baltimore health department and a consumer advocacy group are urging the Trump administration to sidestep patents on a pair of opioid overdose antidotes in order to combat the opioid crisis.

In a letter to the White House, they argue the Trump administration should use a little-known federal law that would permit the government to side step patents on two brand-name medicines — Narcan and Evzio. There are older forms of naloxone, which is widely used to reverse the effect of opioid and heroin overdoses, but these two newer versions were the first to be approved for community use.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.